Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Section of Gastroenterology and Hepatology, West Virginia University School of Medicine, Morgantown, WV 26506, USA.
Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
J Infect Public Health. 2023 May;16(5):673-679. doi: 10.1016/j.jiph.2023.02.008. Epub 2023 Feb 13.
People living with human immunodeficiency virus (PLWH) are at an increased risk of nonalcoholic fatty liver disease (NAFLD) but how these patients react to COVID-19 infection is unclear. We examined the clinical characteristics and outcomes of patients with and without nonalcoholic fatty liver disease (NAFLD) among people living with human immunodeficiency virus (PLWH) diagnosed with COVID-19.
A multicenter, retrospective cohort study was conducted using TriNetX. Participants diagnosed with COVID-19 between January 20, 2020, and October 31, 2021, in PLWH were identified and divided into cohorts based on preexisting NAFLD. The primary outcome was all-cause mortality, and secondary outcomes were hospitalization, severe disease, critical care, need for mechanical ventilation, and acute kidney injury(AKI). Propensity score matching (PSM) mitigated the imbalance among group covariates. Risk ratios (RR) with 95 % confidence intervals (CI) were calculated.
Of the 5012 PLWH identified with confirmed COVID-19 during the study period, 563 had a diagnosis of NAFLD. After PSM, both groups were well-matched with 561 patients. The primary outcome did not differ between the cohorts at 30-days, even after a fully adjusted analysis, and the risk of all-cause mortality did not differ at 60 and 90 days. NAFLD had a significantly higher risk for hospitalization rates (RR 1.32; 95 % CI, 1.06-1.63) and AKI (RR 2.55; 95 % CI 1.42-4.57) than the non-NAFLD group at 30 days. No other differences were detected in other secondary outcome measures.
Preexisting NAFLD is associated with an increased risk for hospitalization and AKI among PLWH infected with COVID-19. The potential role of NAFLD in developing severe COVID-19 among PLWH remains to be elucidated in future studies. Still, this study indicates the need for careful monitoring of this at-risk population.
人类免疫缺陷病毒(PLWH)感染者患非酒精性脂肪性肝病(NAFLD)的风险增加,但这些患者对 COVID-19 感染的反应尚不清楚。我们研究了确诊 COVID-19 的 PLWH 中患有和不患有非酒精性脂肪性肝病(NAFLD)患者的临床特征和结局。
采用 TriNetX 进行多中心回顾性队列研究。于 2020 年 1 月 20 日至 2021 年 10 月 31 日期间,确定了在 PLWH 中诊断为 COVID-19 的患者,并根据预先存在的 NAFLD 将其分为队列。主要结局是全因死亡率,次要结局是住院、重症、重症监护、需要机械通气和急性肾损伤(AKI)。倾向评分匹配(PSM)减轻了组间协变量的不平衡。计算了风险比(RR)及其 95%置信区间(CI)。
在研究期间,在 5012 名确诊 COVID-19 的 PLWH 中,有 563 名患有 NAFLD。经 PSM 后,两组在 561 名患者中匹配良好。即使经过完全调整分析,两组在 30 天时的主要结局也没有差异,60 天和 90 天时的全因死亡率风险也没有差异。NAFLD 组在 30 天时的住院率(RR 1.32;95%CI,1.06-1.63)和 AKI(RR 2.55;95%CI,1.42-4.57)的风险明显高于非 NAFLD 组。在其他次要结局指标中没有发现其他差异。
在感染 COVID-19 的 PLWH 中,预先存在的 NAFLD 与住院和 AKI 的风险增加有关。NAFLD 在 PLWH 中发生严重 COVID-19 的潜在作用仍有待进一步研究阐明。尽管如此,本研究表明需要对这一高危人群进行仔细监测。